AXQ Capital LP Purchases New Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

AXQ Capital LP acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 19,753 shares of the company’s stock, valued at approximately $110,000.

Several other hedge funds and other institutional investors also recently modified their holdings of FDMT. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter worth $295,000. Intech Investment Management LLC purchased a new position in 4D Molecular Therapeutics during the 3rd quarter worth $268,000. Algert Global LLC lifted its stake in shares of 4D Molecular Therapeutics by 342.7% in the 3rd quarter. Algert Global LLC now owns 73,436 shares of the company’s stock worth $794,000 after acquiring an additional 56,848 shares during the period. Walleye Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $912,000. Finally, Braidwell LP raised its holdings in 4D Molecular Therapeutics by 231.7% during the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on FDMT. Morgan Stanley lowered their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Bank of America dropped their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Royal Bank of Canada reduced their target price on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Chardan Capital decreased their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.63.

4D Molecular Therapeutics Trading Up 0.3 %

Shares of NASDAQ FDMT opened at $3.93 on Tuesday. The company’s 50-day moving average price is $4.68 and its 200 day moving average price is $7.30. 4D Molecular Therapeutics, Inc. has a 52 week low of $3.58 and a 52 week high of $36.25. The stock has a market cap of $181.97 million, a price-to-earnings ratio of -1.38 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). As a group, research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.